Abstract: The invention provides a process for the production of a monolithic implant for use in tissue engineering, the process comprising the steps of plasticizing at least one biocompatible material into a paste, extruding the paste through a die, and drying the extruded material to eliminate an aqueous and/or non-aqueous component. The invention also relates to a monolithic implant as thereby manufactured, and the use of such an implant as a scaffold for tissue-engineering and as a transplant tissue in reconstructive or replacement surgery.

Abstract: An electrode for electrochemical analysis is described, the electrode comprising: an insulating surface; a three-dimensional network of carbon nanotubes situated on the insulating surface; and an electrically conducting material in electrical contact with the carbon nanotubes; wherein the carbon nanotubes are oriented substantially parallel to the insulating surface. Also described is a method of manufacturing the electrode, and a method of electrochemically analysing a solution using electrodes of this type, and an associated assay device or kit.

Abstract: The invention relates to diagnostic devices, which are capable of characterising gases and other volatile organic compounds (VOCs) present in the gastrointestinal tract, for diagnosing diseases. The invention extends to apparatuses for use in the in vivo detection and characterisation of gases and VOCs, and to methods for diagnosing diseases.

Abstract: The invention concerns the role of Glo 1 in the prevention and reversal of proteomic and genomic damage by carbonyl substrates thereof and, in particular, therapeutics that promote Glo 1 production.

Abstract: A method of producing a transparent electrode suitable for use in an organic semiconductor photovoltaic device. First and second silanes (3) are deposited from the vapour phase on a substrate (1) and bind to the surface of the substrate. A metal film (4) is then deposited from the vapour phase and binds to both the first and second silanes so as to produce a transparent metal layer having a thickness which is no greater than about 15 nanometres. The first silane is a non-amino functional silane and the second silane is an aminofunctional silane. The electrode may be flexible, using a polymer substrate (1). The metal film (4) may be provided with a plurality of apertures (5), provided for example by masking the substrate with microspheres (2) while depositing the metal and subsequently removing the microspheres, and/or annealing the metal so that apertures appear.

Abstract: A method comprises bonding a silicon wafer or silicon-on-insulator wafer having a monocrystalline silicon surface region and a wafer-like carrier comprising silicon carbide so as to form a composite wafer having a surface with the monocrystalline silicon surface region for silicon carbide heterogrowth, such as heteroepitaxy. The composite wafer can help avoid wafer bow.

Abstract: Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Co-administration of cloned DI influenza A virus with a lethal dose of virulent influenza A virus conferred protection in mice compared to a control of inactivated cloned DI influenza A virus. Control mice which received only cloned DI influenza A virus and no lethal challenge of virulent influenza A virus were not protected three weeks later on lethal challenge with infective virus. Cloned DI influenza A virus of one subtype is found to act in vivo as an effective antiviral against the same or any other sub-type of influenza A virus. The antiviral effect has been found to have both a therapeutic and a prophylactic application against influenza A infection in humans, mammals and birds.

Abstract: Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Cloned DI virus is then used in tests on mice and ferrets given a lethal challenge of wild-type influenza A virus. When cloned DI influenza A virus is co-administered with a lethal dose of virulent influenza A virus, mice are protected compared to a control of inactivated cloned DI influenza A virus. Mice which survived the administration of cloned DI influenza A virus and infective challenge virus are three weeks later still protected against lethal challenge with infective virus. Control mice which received only cloned DI influenza A virus and no lethal challenge are not protected three weeks later on lethal challenge with infective virus.

Abstract: The invention relates to a biosensor comprising an electrically conductive substrate, with a first layer comprising Ruthenium Purple formed on the substrate, a second layer comprising polyaniline or a derivative thereof comprising one or more non-polar substituents formed on the first layer, and a third layer comprising one or more enzymes trapped within a matrix formed on the second layer. The biosensor is for use in the detection of analytes such as purines and derivatives thereof, particularly in the detection of hypoxanthine.

Abstract: Sensor device for ion channel recordings; liquid-liquid measurements and resistive pulse particle counting comprising; at least one sensor element; the element comprising a diamond thin film substrate and a pore which is a nanopore or a micropore included in the substrate. This device may be used in analysis, for instance the device may be used for single molecule detection of an apialyte (e.g. DNA), for the analysis of interactions between a sensor element and an analyte, for the detection of pore forming entities, or for the determination of ion transfer.

Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.

Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.

Abstract: This invention relates to the field of heat-driven cooling devices, heat pumps or thermal transformers, in particular to those devices, known as sorption devices, which employ an ad- or absorbent material as a chemical compressor to raise the pressure of a refrigerant gas. This invention is particularly concerned with a heat exchanger suitable for use as a generator in a sorption device.

Abstract: A photosensitive optoelectronic device (1) comprises a plurality of organic semiconductor sub-cells (10, 11, 12, 13) arranged in a stack between electrodes (3, 5), each sub-cell comprising donor material (14, 16, 23, 25) and acceptor material (15, 17, 24, 26) providing a heterojunction. There is a recombination layer (19, 22, 28) between adjacent sub-cells. The sub-cells are arranged in two groups (20, 29). The sub-cells (10, 11; 12, 13) within a group (20; 29) are responsive over substantially the same part of the light spectrum. The groups (20, 29) differ substantially from each other in respect of the parts of the light spectrum over which their respective sub-cells are responsive.

Abstract: The invention relates to histology analyses, and in particular, to the assessment of pathological tissues to aid in the diagnosis of disease characterised by specific pathologies, for example cancer. The invention provides methods and apparatuses for analysing tissue samples, as well as computer-readable media programmed with software for carrying out these diagnostic methods.

Abstract: The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.

Abstract: The application discloses a method of making an antibody molecule, the antibody containing an immunoglobulin heavy chain comprising a ?3 domain or a mu domain, the method comprising: (a) Providing a nucleotide sequence encoding the immunoglobulin heavy chain; (b) Modifying the nucleotide sequence in the region of the nucleotide sequence encoding the C-terminus 18 amino acids of the completed heavy chain to remove, or reduce the effectiveness of, one or more vacuolar targeting signal sequences to form a modified nucleotide sequence; (c) Inserting the modified nucleotide sequence into a host cell; and (d) Causing the host cell to express the modified nucleotide sequence to form the modified antibody heavy chain and secrete the modified antibody heavy chain from the host cell. This improves the secretion of the antibody from, for example, plant cells. Methods of adding J-chain binding activity to antibodies are also provided. The modified antibodies and their use is also disclosed.

Abstract: A gas-sensing semiconductor device 1? is fabricated on a silicon substrate 2? having a thin silicon dioxide insulating layer 3? in which a resistive heater 6 made of doped single crystal silicon formed simultaneously with source and drain regions of CMOS circuitry is embedded. The device 1? includes a sensing area provided with a gas-sensitive layer 9? separated from the heater 6? by an insulating layer 4?. As one of the final fabrication steps, the substrate 2? is back-etched so as to form a thin membrane in the sensing area. The heater 6? has a generally circular-shaped structure surrounding a heat spreading plate 16?, and consists of two sets 20?, 21? of meandering resistors having arcuate portions nested within one another and interconnected in labyrinthine form.

Abstract: The present invention relates to osmium compounds of formula (I), their preparation and use in methods of treatment, particularly for cancer treatment.

Abstract: The invention provides a method of identifying a peptide or protein capable of binding a ligand which comprises: (i) providing a support, the support comprising a photoreactive group; (ii) reacting the photoreactive group with a ligand to attach the ligand to the support and produce a supported ligand; (iii) providing an expression library comprising a plurality of members, each member expressing a different peptide or protein; (iv) screening the expression library to identify one or more peptides or proteins which bind to the ligand; (v) isolating the member or each member of the library which expresses a peptide or protein which binds to the ligand; and (vi) identifying the peptide or protein which binds to the ligand. Supported photo-reactive compounds are disclosed comprising a photo-reactive group attached to a support via a spacer and a dendritic group, the dendritic group comprising attached thereto, optionally via a spacer, at least one further photo-reactive group and/or a second functional group.